Literature DB >> 226860

In vitro and in vivo kinetic analysis of the interaction of a norbornyl derivative of propranolol with beta-adrenergic receptors of brain and C6 glioma cells; an irreversible or slowly reversible ligand.

M Lucas, V Homburger, A Dolphin, J Bockaert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 226860

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN： 0026-895X            Impact factor:   4.436


× No keyword cloud information.
  6 in total

1.  Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists.

Authors:  David A Sykes; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Binding characteristics of (+)-, (+/-)- and (-)-[125iodo] cyanopindolol to guinea-pig left ventricle membranes.

Authors:  D Hoyer; G Engel; R Berthold
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-03       Impact factor: 3.000

3.  Carbostyril-based beta-adrenergic agonists: evidence for long lasting or apparent irreversible receptor binding and activation of adenylate cyclase activity in vitro.

Authors:  K M Standifer; J Pitha; S P Baker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

4.  Dissociation constants of isoprenaline and orciprenaline and their relative efficacies on guinea-pig isolated atria determined by use of an irreversible beta-adrenoceptor antagonist.

Authors:  K J Broadley; C D Nicholson
Journal:  Br J Pharmacol       Date:  1981-04       Impact factor: 8.739

5.  Irreversible blockade of beta-adrenergic receptors with a bromoacetyl derivative of pindolol.

Authors:  V Homburger; H Gozlan; R Bouhelal; M Lucas; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-01       Impact factor: 3.000

6.  Beta-adrenoceptor blocking effects and plasma levels of bornaprolol and propranolol in man.

Authors:  C Thuillez; C Richer; P Duhazé; L Bergougnan; J F Giudicelli
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.